Compare GOTU & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOTU | MRVI |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 580.9M | 449.6M |
| IPO Year | 2019 | 2020 |
| Metric | GOTU | MRVI |
|---|---|---|
| Price | $2.43 | $3.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.57 |
| AVG Volume (30 Days) | 410.4K | ★ 1.3M |
| Earning Date | 11-26-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $821,732,499.00 | $192,435,000.00 |
| Revenue This Year | $36.84 | N/A |
| Revenue Next Year | $16.27 | $9.04 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 49.01 | N/A |
| 52 Week Low | $1.87 | $1.67 |
| 52 Week High | $4.56 | $6.21 |
| Indicator | GOTU | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 49.89 |
| Support Level | $2.30 | $3.19 |
| Resistance Level | $2.39 | $3.37 |
| Average True Range (ATR) | 0.07 | 0.16 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 88.07 | 42.73 |
Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.